Abstract
BackgroundDue to their nanometric scale (50 nm) along with their biomimetic properties, lipid nanocapsules loaded with Rhenium-188 (LNC188Re-SSS) constitute a promising radiopharmaceutical carrier for hepatocellular carcinoma treatment as its size may improve tumor penetration in comparison with microspheres devices. This study was conducted to confirm the feasibility and to assess the efficacy of internal radiation with LNC188Re-SSS in a chemically induced hepatocellular carcinoma rat model.Methodology/Principal FindingsAnimals were treated with an injection of LNC188Re-SSS (80 MBq or 120 MBq). The treated animals (80 MBq, n = 12; 120 MBq, n = 11) were compared with sham (n = 12), blank LNC (n = 7) and 188Re-perrhenate (n = 4) animals. The evaluation criteria included rat survival, tumor volume assessment, and vascular endothelial growth factor quantification. Following treatment with LNC188Re-SSS (80 MBq) therapeutic efficiency was demonstrated by an increase in the median survival from 54 to 107% compared with control groups with up to 7 long-term survivors in the LNC188Re-SSS group. Decreased vascular endothelial growth factor expression in the treated rats could indicate alterations in the angiogenesis process.Conclusions/SignificanceOverall, these results demonstrate that internal radiation with LNC188Re-SSS is a promising new strategy for hepatocellular carcinoma treatment.
Highlights
Hepatocellular carcinoma (HCC) is the fifth most common malignant tumor worldwide
Conclusions/Significance: Overall, these results demonstrate that internal radiation with LNC188Re-SSS is a promising new strategy for hepatocellular carcinoma treatment
The use of lipid nanocapsules (LNC), with a structure similar to lipoproteins, could represent a promising therapeutic modality for HCC management, as they modify the biodistribution of entrapped therapeutic agents [12,13,14]
Summary
Hepatocellular carcinoma (HCC) is the fifth most common malignant tumor worldwide. The prognosis of HCC remains extremely poor, and a curative treatment (liver transplantation, surgical resection, and radiofrequency ablation) can only be carried out in approximately 25% to 30% of cases [1]. Selective internal radiotherapy (SIRT) aims to deliver high tumoricidal doses while limiting the development of RILD This locoregional strategy is defined as the infusion of radioactive carrier including microsphere of Yttrium-90, Iodine-131 iodized oil or similar agent into the hepatic artery [3]. Given the hypervascularity of HCC, 90Y-microspheres injected into the hepatic artery will spread throughout the liver or confined to certain areas, where they can stop blood supply of the tumor by the embolisation process Due to their nanometric scale (50 nm) along with their biomimetic properties, lipid nanocapsules loaded with Rhenium-188 (LNC188Re-SSS) constitute a promising radiopharmaceutical carrier for hepatocellular carcinoma treatment as its size may improve tumor penetration in comparison with microspheres devices. This study was conducted to confirm the feasibility and to assess the efficacy of internal radiation with LNC188Re-SSS in a chemically induced hepatocellular carcinoma rat model
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
